Close Menu
Home › Biocartis Gets CE Mark for Idylla NRAS-BRAF Mutation Test

Biocartis Gets CE Mark for Idylla NRAS-BRAF Mutation Test

Dec 15, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Biocartis said today that its tissue-based Idylla NRAS-BRAF mutation test has been CE marked and can now be sold throughout the European Economic Area.

According to the company, the combination of the new NRAS-BRAF mutation test with its existing KRAS assay means that it can offer customers a complete solution for clinical testing of metastatic colorectal cancers, as recommended by the most recent professional guidelines.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
14
Featured Webinar

High-Performance Variant Detection in Somatic Cancer Testing with an Integrated NGS Solution

Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

Dec
02
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.   

What's Popular?

In Molecular Diagnostics

  1. Ancestry Begins Genetic Testing Services for Health

    Premium

  2. Natera Plans Stock Offering Worth up to $201.3M; Expects Q3 Revenue Gain Above Consensus Estimate

  3. Abbott Q3 Diagnostics Revenues Rise 5 Percent, MDx Revenues Decline

  4. Inivata Collecting Evidence for Liquid Biopsy in Immunotherapy Prediction, Response Monitoring

    Premium

  5. Exact Sciences, Mayo Clinic Launch Real-World Impact Study for Cologuard

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.